Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 2

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 3(4)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06890832Phase 2Not Yet Recruiting

A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer

Role: lead

NCT03671044Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Role: lead

NCT06608641Phase 3Active Not Recruiting

Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Role: lead

NCT06867042Phase 2Not Yet Recruiting

Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment

Role: lead

NCT06867562Phase 3Not Yet Recruiting

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

Role: lead

NCT04315792Phase 3Completed

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Role: lead

NCT01957995Phase 1Completed

Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors

Role: collaborator

All 7 trials loaded